Treatment-related cardiac toxicity has been an important concern in the HER2-positive breast cancer population because it might prevent patients from receiving further HER2-targeted therapy and ultimately affect outcomes as well as survivorship. The gene discussed is ERBB2; the disease is breast cancer.